UK Pension Superfunds Set to Double Deal Volume in 2026

UK pension superfund transaction counts are on track to double in 2026, rising from four completed deals to roughly eight to ten as two new providers join Clara Pensions and TPT Retirement Solutions (LCP, November 2025). Superfund pricing typically runs 10 to 15 percent below insurer buyout cost, a wedge scheme actuaries must model against reduced member protection before recommending it to trustees.

Why Superfund Volume Is Accelerating in 2026

Two forces are converging on the superfund market at once, and neither is new on its own. UK defined benefit funding has strengthened dramatically since the 2022 gilt crisis, and separately, insurer bulk annuity capacity has not kept pace with the volume of schemes now ready to transact. WTW's February 2026 outlook puts total UK pension risk transfer volume at £70 billion for the year, roughly 15 percent above 2025, split between more than £50 billion in bulk annuities and up to £20 billion in longevity swaps (WTW, February 2026). LCP separately forecasts £40 billion to £55 billion in buy-in and buyout volume and projects more than 150,000 members will move through to full buyout in 2026, roughly three times 2024's throughput (LCP Pension Risk Transfer Report, November 2025). That is a lot of insurer capacity being absorbed by a small number of very large, well-funded schemes able to pay for priority in the queue.

The schemes left behind in that queue are not badly funded. They are, more often, mid-sized or smaller schemes for whom the fixed transaction costs of a bespoke insurer process, and the multi-year wait for an underwriting slot at the larger carriers, make buyout a real but distant destination. Industry estimates place buyout queues for larger schemes at three to five years once a scheme first approaches the market, driven by data cleansing backlogs, administrator capacity constraints, and the sheer volume insurers are processing (Pensions Expert, 2026). Laura Amin, partner and head of DB consolidation at LCP, has described 2026 as a "pivotal year" for the superfund market precisely because supply-side and demand-side pressures are arriving together: better scheme funding pushing more schemes toward an endgame decision, and insurer capacity constraints making the traditional buyout path slower than schemes would like (Corporate Adviser, 2026).

Regulatory friction has also eased. The Pension Schemes Act 2026 establishes, for the first time, a statutory authorization and supervision framework for superfunds, replacing the interim regime The Pensions Regulator has operated since 2020. A consultation on the detailed regulations is expected in mid-2026, with the full regime not applying until early 2028 (Norton Rose Fulbright, 2026). That timeline matters: the doubling of deal volume LCP forecasts for 2026 happens under the existing interim TPR assessment process, not the new statutory regime, meaning current transactions still rely on TPR's discretionary sign-off rather than a codified authorization standard. Trustees transacting in the next 18 months are operating in the gap between the two regimes.

How a Superfund Actually Differs From an Insurer Buyout

The structural distinction is not cosmetic. An insurer buyout is a contract of insurance: the scheme's liabilities become the insurer's liabilities, the insurer is authorized and supervised by the Prudential Regulation Authority under Solvency II capital rules, and if the insurer fails, the Financial Services Compensation Scheme provides a 100 percent guarantee for existing pension policyholders. A superfund is not an insurance contract. It is a consolidation vehicle regulated by The Pensions Regulator, member benefits are backed by a ring-fenced capital buffer rather than a Solvency II balance sheet, and there is no FSCS-equivalent guarantee sitting behind it. If the capital buffer and scheme assets together prove insufficient, members have no statutory compensation scheme to fall back on in the way insurer buyout members do.

That capital buffer is not arbitrary. Under TPR's interim regime, the buffer must be sized so that, combined with scheme assets, there is a 99 percent probability of the scheme remaining funded at or above its technical provisions over a rolling five-year horizon. Read carefully, that standard is a repeating one-in-a-hundred tail risk, not a one-time test at entry. Over a superfund's multi-decade run-off, a capital adequacy test re-applied every five years compounds differently than a single point-in-time solvency check, and it is the actuarial detail trustees most often skip past when comparing a superfund quote to a Solvency II-backed insurer quote on a like-for-like basis.

The pricing basis diverges from that same structural difference. Superfund technical provisions must be calculated using a discount rate of gilts plus 0.75 percent per annum, a fixed regulatory margin set by TPR. Insurer buyout pricing, by contrast, is built from each carrier's own asset portfolio, typically referencing swap rates and credit spreads on the illiquid assets (infrastructure debt, equity release mortgages, private placements) backing the annuity book, with the credit spread varying by insurer and by the specific liability profile being priced. When insurers are earning attractive spread income on assets like these, their buyout pricing can undercut a superfund's fixed gilts-plus basis entirely, which is part of why TPR's own engagement response flagged that "some insurers can offer cheaper pricing than superfunds" under current conditions, undermining the superfund's intended cost advantage in certain deals (The Pensions Regulator, Superfunds Engagement Response). The headline 10 to 15 percent discount Aon has quantified for superfunds versus buyout therefore is not universal. It reflects the segment of the market, generally smaller or less straightforwardly priced liabilities, where insurer appetite and pricing are thinner and a superfund's simpler, standardized approach to onboarding wins on cost.

The Actuarial Pricing Wedge: When Cheaper Is Genuinely Cheaper

The core diagnostic question for a scheme actuary comparing a superfund quote to a buyout quote is not "which number is lower." It is whether the lower superfund price reflects genuine efficiency, standardized onboarding, lower transaction costs, economies of scale across a shared capital buffer, or whether it reflects a lower-quality risk transfer being priced to look competitive against a fuller guarantee. Both explanations can be true simultaneously, and disentangling them requires the actuary to price the specific difference in security being purchased, not just compare headline transfer costs.

Clara Pensions' completed transactions illustrate the mechanics concretely. Clara's deal with the Debenhams Retirement Scheme, its second transaction and the first involving a scheme that had already entered Pension Protection Fund assessment, restored 10,400 members from PPF compensation levels (typically 90 percent of full benefit for non-pensioners, with back-payments totaling £4 million for members who had already received reduced payments) to 100 percent of promised pension, backed by an additional £34 million of dedicated Clara capital on top of the £600 million transferred (Clara Pensions, Norton Rose Fulbright). That is a case where the superfund is unambiguously improving member outcomes relative to the counterfactual (continued PPF assessment), not trading security for price. Clara has since completed the Wates Pension Fund (£210 million, 1,500 members, December 2024), the Church Mission Society Pension Scheme (£55 million, 730 members, 2025), and the Videndum DB Pension Scheme (£43 million, 500 members, 2026, its first transaction under a new small-scheme structure), bringing its completed total to five (Clara Pensions; Professional Pensions, 2026).

The Debenhams case is instructive precisely because it is not the typical comparison trustees face. Most schemes evaluating a superfund are not coming out of PPF assessment; they are comparing a superfund quote against a live insurer buyout quote for a fully solvent scheme with an ongoing sponsor. In that more common scenario, the actuarial question is sharper: is the superfund's capital buffer, sized to a 99 percent five-year confidence standard under a gilts-plus-0.75-percent valuation basis, actually a comparable substitute for a Solvency II insurer balance sheet backed by an FSCS guarantee? For most schemes the honest answer is no, it is a different and generally lower tier of security, and the 10 to 15 percent price difference is the market's implied cost of that gap. Trustees who treat the two quotes as substitutable line items in a beauty parade, rather than as different risk transfer products with different residual exposures, are making a decision without pricing what they are actually buying.

The New Entrant Landscape: From Monopoly to a Real Market

Since Clara's first transaction in November 2023, it has effectively operated as the only active commercial superfund in the UK market. That changes materially in 2026. TPT Retirement Solutions entered TPR's assessment process in October 2025 with a £1 billion "run-on" model that shares surplus with members, a structural departure from Clara's bridge-to-buyout approach, in which the superfund holds liabilities only until conditions allow an eventual insurer buyout (Corporate Adviser, 2026). LCP expects two further new entrants to complete assessment during 2026, which would take the market from one active provider at the start of the year to four by year end.

A four-provider market changes the actuarial due diligence burden on trustees in a way that a one-provider market did not. With only Clara active, the practical question was binary: is a superfund transfer appropriate for this scheme, yes or no. With four providers offering genuinely different structures, bridge-to-buyout versus run-on being the clearest split, trustees and their advisors must now underwrite provider solvency, investment strategy, and governance quality across multiple counterparties with different risk profiles, not just evaluate the superfund concept in the abstract. A run-on model that shares surplus with members carries different long-run member incentive and governance dynamics than a bridge model built to exit into an insurer buyout within five to ten years, and the actuarial assumptions trustees should stress-test, particularly around the sustainability of the sponsor's ongoing capital commitment, differ meaningfully between the two.

More providers should, in principle, compress pricing further and reduce the oligopoly risk that concentrated capacity has created in the insurer buyout market, where three of eleven active bulk annuity insurers changed ownership to international investors during 2025 and 2026. But a wider provider set also means trustees can no longer default to "Clara is the only game in town" as an implicit due diligence shortcut. Each new entrant needs its own capital adequacy assessment, and the actuarial advisory market itself has to build comparative frameworks across superfund structures that, until this year, did not really exist because there was only one structure to compare against.

Quantifying the Residual Risk Gap

The clearest way to make the superfund-versus-buyout tradeoff concrete for a trustee board is to translate the regulatory capital standards into a plain probability statement. An insurer buyout, backed by Solvency II capital held to a 99.5 percent one-year value-at-risk standard plus the FSCS guarantee behind it, leaves members with a residual probability of shortfall that is vanishingly small and, in practice, backstopped entirely in the rare event it does occur. A superfund's capital buffer, sized to a 99 percent probability of remaining above technical provisions over a rolling five-year window with no compensation scheme behind it, leaves a non-trivial and recurring tail exposure: roughly a one-in-a-hundred chance, reassessed every five years across a run-off that can last decades, that the buffer proves insufficient at some point along the way, with no backstop if it does.

That is not a reason to reject superfunds. It is the reason trustees need a number, not a narrative, when they take the recommendation to their board. A scheme actuary advising on a superfund transfer should be able to state explicitly: this transaction accepts a residual probability of shortfall on the order of one percent per five-year window, in exchange for a price roughly 10 to 15 percent below the insurer alternative and a materially faster path out of the sponsor's balance sheet than a three-to-five-year buyout queue. Framed that way, for a sponsor facing genuine covenant deterioration risk over the coming years, or for a scheme whose small size means insurer pricing is uncompetitive regardless of queue position, the superfund trade can be the actuarially correct answer. For a well-funded, patient scheme with a strong ongoing sponsor, the calculus tips the other way, because the cost of waiting in the buyout queue is mostly time, while the cost of the superfund route is a permanent, quantifiable reduction in member security.

What Would It Take for a US Superfund Market to Function

The UK superfund model has been floated repeatedly as a template for resolving distressed and "zombie" multiemployer defined benefit plans in the United States, and the two systems' underlying architecture explains why the concept has not translated directly. In the UK, TPR can authorize a private consolidator to accept a scheme's assets and liabilities outright, replacing the sponsor's covenant with a capital buffer under a bespoke regulatory standard built for exactly this purpose. ERISA has no equivalent mechanism. The Pension Benefit Guaranty Corporation's multiemployer program does not insure against plan termination the way its single-employer program does; instead, when a multiemployer plan becomes insolvent, PBGC provides financial assistance in the form of loans, and its principal consolidation tools are plan mergers and "partition," where PBGC itself assumes responsibility for a portion of a distressed plan's obligations rather than transferring the plan to a private capital-backed vehicle.

For a UK-style commercial superfund to operate in the US, Congress would need to create an authorization framework that does not currently exist in ERISA: a legal basis for a private, non-insurance entity to accept full transfer of pension liabilities from either a single-employer or multiemployer plan, subject to a capital adequacy standard analogous to TPR's 99 percent five-year test, with clear rules on what protection (if any) PBGC-equivalent coverage would extend to members transferred into it. On the single-employer side, the PBGC's flat-rate premium of $111 per participant in 2026, up from $106 in 2025 and $35 as recently as 2012, already creates the same cost-of-deferral pressure that is pushing UK schemes toward faster exits (PBGC, 2026), but standard and distress termination rules route sponsors toward an insurer buyout, not a superfund-style consolidator, because no such consolidator is legally recognized. The UK's four-year build, from TPR's first interim guidance in 2018 to a statutory Pension Schemes Act in 2026, is itself a reasonable estimate of the legislative and regulatory runway a US equivalent would require, assuming Congress had the appetite to start.

Why This Matters for Actuaries

The superfund route is moving from a niche curiosity to a mainstream third option in the UK de-risking toolkit, and that shift creates direct new work and new risk for pension actuaries. Trustee boards are going to keep receiving superfund quotes alongside buyout quotes, in growing volume, from a growing set of providers, and the headline price comparison will keep understating the difference in what is actually being purchased. Scheme actuaries who can decompose a superfund quote into its component parts, the discount rate basis, the capital buffer's confidence standard, the absence of an FSCS-equivalent guarantee, and translate that into a plain residual-risk number for trustees, are providing exactly the analysis a beauty-parade comparison cannot. As the provider landscape widens from one to four in a single year, that comparative analysis needs to extend across structurally different models, bridge-to-buyout versus run-on, not just across price. And for actuaries with one eye on the US market, the UK's superfund experience is becoming the clearest available data set for what a private consolidation vehicle for distressed and legacy DB liabilities could look like, if ERISA ever built the statutory scaffolding to support one.